Y79/Y79/Y79/人视网膜母细胞瘤

Y79/Y79细胞系/Y79细胞株/Y79人视网膜母细胞瘤

Cell line name Y-79

Synonyms Y79; GM01232; GM01232E

Accession CVCL_1893

Resource Identification Initiative To cite this cell line use: Y-79 (RRID:CVCL_1893)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Population: Caucasian.

Doubling time: 52 hours (PubMed=4135597); 47 hours (PubMed=25326674); 24-28 hours (DOI=10.5005/jp-journals-10082-02230); ~40 hours (DSMZ=ACC-246).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Anecdotal: Named Y-79 because it was the result of the 79th attempt of a group at Yale to establish a retinoblastoma cell line.

Derived from site: In situ; Eye, globe; UBERON=UBERON_0010230.

PubMed=7689221; DOI=10.1073/pnas.90.16.7578; PMCID=PMC47185

Godbout R., Squire J.A.

Amplification of a DEAD box protein gene in retinoblastoma cell lines.

Proc. Natl. Acad. Sci. U.S.A. 90:7578-7582(1993)

 

PubMed=7499444; DOI=10.1007/BF01213319

Inomata M., Saijo N., Kawashima K., Kaneko A., Fujiwara Y., Kunikane H., Tanaka Y.

Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.

J. Cancer Res. Clin. Oncol. 121:729-738(1995)

 

PubMed=18036396; DOI=10.1016/j.cancergencyto.2007.08.014

Paderova J., Orlic-Milacic M., Yoshimoto M., da Cunha Santos G., Gallie B.L., Squire J.A.

Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses.

Cancer Genet. Cytogenet. 179:102-111(2007)

 

PubMed=18799932; DOI=10.1097/MPH.0b013e31816e232d

Kim J.H., Kim J.H., Yu Y.S., Kim D.H., Kim Y.K., Kim K.-W.

Comparative genomic hybridization analysis of newly established retinoblastoma cell lines of adherent growth compared with Y79 of nonadherent growth.

J. Pediatr. Hematol. Oncol. 30:571-574(2008)

 

PubMed=19686387; DOI=10.1111/j.1471-4159.2009.06322.x; PMCID=PMC3726384

Glubrecht D.D., Kim J.-H., Russell L., Bamforth J.S., Godbout R.

Differential CRX and OTX2 expression in human retina and retinoblastoma.

J. Neurochem. 111:250-263(2009)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=21697133; DOI=10.1167/iovs.11-7479

Oshikawa M., Tsutsui C., Ikegami T., Fuchida Y., Matsubara M., Toyama S., Usami R., Ohtoko K., Kato S.

Full-length transcriptome analysis of human retina-derived cell lines ARPE-19 and Y79 using the vector-capping method.

Invest. Ophthalmol. Vis. Sci. 52:6662-6670(2011)

 

PubMed=23498719; DOI=10.1016/S1470-2045(13)70045-7

Rushlow D.E., Mol B.M., Kennett J.Y., Yee S., Pajovic S., Theriault B.L., Prigoda-Lee N.L., Spencer C., Dimaras H., Corson T.W., Pang R., Massey C., Godbout R., Jiang Z., Zacksenhaus E., Paton K., Moll A.C., Houdayer C., Raizis A., Halliday W., Lam W.L., Boutros P.C., Lohmann D.R., Dorsman J.C., Gallie B.L.

Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

Lancet Oncol. 14:327-334(2013)

 

PubMed=25326674; DOI=10.1007/s00418-014-1285-z

Busch M.A., Philippeit C., Weise A., Dunker N.

Re-characterization of established human retinoblastoma cell lines.

Histochem. Cell Biol. 143:325-338(2015)

 

PubMed=27050416; DOI=10.1371/journal.pone.0153011; PMCID=PMC4822873

Ferrario A., Luna M.C., Rucker N., Wong S., Lederman A., Kim J., Gomer C.J.

Targeting survivin enhances chemosensitivity in retinoblastoma cells and orthotopic tumors.

PLoS ONE 11:E0153011-E0153011(2016)

 

PubMed=27115612; DOI=10.1371/journal.pone.0153323; PMCID=PMC4846005

Kooi I.E., Mol B.M., Massink M.P.G., de Jong M.C., de Graaf P., van der Valk P., Meijers-Heijboer H., Kaspers G.J.L., Moll A.C., te Riele H., Cloos J., Dorsman J.C.

A meta-analysis of retinoblastoma copy numbers refines the list of possible driver genes involved in tumor progression.

PLoS ONE 11:E0153323-E0153323(2016)

 

DOI=10.3969/j.issn.1673-713X.2017.04.002

Song W.-P., Zhang C.-Y., Zhang Y., Li Y., Cao R., Ye C., Zhang L., Shao R.-G., Li L., Zhao J.-Y.

Generation of etoposide-resistant subline of human retinoblastoma Y79 cells and preliminary study of its resistance mechanism.

Zhongguo Yiyao Sheng Wu Jishu 12:297-302(2017)

 

PubMed=29162051; DOI=10.1186/s12885-017-3750-2; PMCID=PMC5698942

Nair R.M., Balla M.M.S., Khan I., Kalathur R.K.R., Kondaiah P., Vemuganti G.K.

In vitro characterization of CD133(lo) cancer stem cells in retinoblastoma Y79 cell line.

BMC Cancer 17:779.1-779.12(2017)